Long-acting protein drugs for the treatment of ocular diseases

Nature Communications

Volumn 8, Issue , 2017, Pages

  Ghosh, Joy G ^a   Nguyen, Andrew A ^a   Bigelow, Chad E ^a   Poor, Stephen ^a   Qiu, Yubin ^a   Rangaswamy, Nalini ^a   Ornberg, Richard ^a   Jackson, Brittany ^a   Mak, Howard ^a   Ezell, Tucker ^a   Kenanova, Vania ^a   De La Cruz, Elisa ^a   Carrion, Ana ^a   Etemad Gilbertson, Bijan ^a   Caro, Roxana Garcia ^a   Zhu, Kan ^a   George, Vinney ^a   Bai, Jirong ^a   Sharma Nahar, Radhika ^a   Shen, Siyuan ^a   Wang, Yiqin ^a   Subramanian, Kulandayan K ^a   Fassbender, Elizabeth ^a   Maker, Michael ^a   Hanks, Shawn ^a   Vrouvlianis, Joanna ^a   Leehy, Barrett ^a   Long, Debby ^a   Prentiss, Melissa ^a   Kansara, Viral ^a   Jaffee, Bruce ^a   Dryja, Thaddeus P ^a   Roguska, Michael ^a   more..

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; AMINO ACID DERIVATIVE; BEVACIZUMAB; BROLUCIZUMAB; HYALURONIC ACID; IMMUNOGLOBULIN F(AB) FRAGMENT; POLYMER; RANIBIZUMAB; VASCULOTROPIN 165; ANGIOGENESIS INHIBITOR; FUSION PROTEIN; VASCULOTROPIN RECEPTOR;

DISEASE TREATMENT; DRUG; ENCAPSULATION; MAMMAL; PEPTIDE; POLYMER; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; EYE DISEASE; IN VIVO STUDY; MALE; MICROENCAPSULATION; NONHUMAN; PROTEIN MODIFICATION; TREATMENT INDICATION; VITREOUS BODY; ANIMAL; CHEMISTRY; DISEASE MODEL; FEMALE; HALF LIFE TIME; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; LEPORIDAE; MACACA FASCICULARIS; METABOLISM; RETINA DISEASE;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

ANGIOGENESIS INHIBITORS; ANIMALS; BEVACIZUMAB; DISEASE MODELS, ANIMAL; FEMALE; HALF-LIFE; HUMANS; HYALURONIC ACID; INTRAVITREAL INJECTIONS; MACACA FASCICULARIS; MALE; RABBITS; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL DISEASES;

EID: 85016129813     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14837     Document Type: Article

References (20)

1. Arnold, J. J., et al. Two-year outcomes of ?treat and extend? intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology 122, 1212-1219 (2015).
2. Oishi, A., et al. Remission and dropout rate of anti-VEGF therapy for age-related macular degeneration. Eur. J. Ophthalmol. 21, 777-782 2011.
3. Finger, R. P., Wiedemann, P., Blumhagen, F., Pohl, K., & Holz, F. G. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study-A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol. 91, 540-546 (2012).
4. Day, S., et al. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am. J. Ophthalmol. 152, 266-272 (2011).
5. Nickerson, C. Engineering the Mechanical Properties of Ocular Tissues (California Institute of Technology, 2005).
6. Balazs, E. A., & Denlinger, J. L. in Aging and Human Visual Function (eds Sekuler, R., & Kline, D.) (Alan R. Liss, Inc., 1982).
7. Sleep, D., Cameron, J., & Evans, L. R. Albumin as a versatile platform for drug half-life extension. Biochim. Biophys. Acta 1830, 5526-5534 (2013).
8. Molokhia, S. A., Jeong, E. K., Higuchi, W. I., & Li, S. K. Transscleral iontophoretic and intravitreal delivery of a macromolecule: study of ocular distribution in vivo and postmortem with MRI. Exp. Eye Res. 88, 418-425 (2009).
9. Necas, J., Bartosikova, L., Brauner, P., & Kolar, J. Hyaluronic acid (hyaluronan): a review. Vet. Med. 53, 397-411 (2008).
10. Fraser, J. R., Laurent, T. C., & Laurent, U. B. Hyaluronan: its nature, distribution, functions and turnover. J. Intern. Med. 242, 27-33 (1997).
11. Laurent, U. B., & Fraser, J. R. Turnover of hyaluronate in the aqueous humour and vitreous body of the rabbit. Exp. Eye Res. 36, 493-503 (1983).
12. Wisniewski, H. G., & Vilcek, J. TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity. Cytokine Growth Factor Rev. 8, 143-156 (1997).
13. Holz, F. G., et al. Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study. Ophthalmology 123, 1080-1089 (2016).
14. Miller, H., Miller, B., & Ryan, S. J. The role of retinal pigment epithelium in the involution of subretinal neovascularization. Invest. Ophthalmol. Vis. Sci. 27, 1644-1652 (1986).
15. Higman, V. A., et al. A refined model for the TSG-6 link module in complex with hyaluronan: use of defined oligosaccharides to probe structure and function. J. Biol. Chem. 289, 5619-5634 (2014).
16. Bansal, P., Garg, S., Sharma, Y., & Venkatesh, P. Posterior segment drug delivery devices: current and novel therapies in development. J. Ocul. Pharmacol. Ther. 32, 135-144 (2016).
17. Peptu, C. A., Popa, M., Savin, C., Popa, R. F., & Ochiuz, L. Modern drug delivery systems for targeting the posterior segment of the eye. Curr. Pharm. Des. 21, 6055-6069 (2015).
18. Binz, H. K., Stumpp, M. T., Forrer, P., Amstutz, P., & Pluckthun, A. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J. Mol. Biol. 332, 489-503 (2003).
19. Vedaldi, A., & Fulkerson, B. VLFeat: An open and portable library of computer vision algorithms. Available at http://www.vlfeat.org/.(2008).
20. Krzystolik, M. G., et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol. 120, 338-346 (2002).